141 related articles for article (PubMed ID: 2104819)
1. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
3. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
5. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Moore DH; Valea F; Crumpler LS; Fowler WC
Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.
Manetta A; Tewari K; Podczaski ES
Gynecol Oncol; 1997 Jul; 66(1):20-6. PubMed ID: 9234915
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
11. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
14. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
15. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Rosen GF; Lurain JR; Newton M
Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Vergote I; Himmelmann A; Frankendal B; Scheistrøen M; Vlachos K; Tropé C
Gynecol Oncol; 1992 Dec; 47(3):282-6. PubMed ID: 1473738
[TBL] [Abstract][Full Text] [Related]
17. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
[TBL] [Abstract][Full Text] [Related]
18. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
19. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
20. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]